Opana Safety Review Will Set Tone For Opioid Regulation Under Trump

FDA’s 2017 advisory committee calendar is extremely light, but the one product focused review on the schedule should be a doozy: a two-day look at safety issues with Endo’s Opana ER as well as generic versions of oxymorphone. The topic is likely to resonate with the Trump Administration and especially Vice President Pence.

Clouds-Lightning-Storm_1200x675

A March review of Endo Pharmaceuticals Inc.’s Opana ER formulation and other versions of oxymorphone will provide an early read on the future of opioid pain drug regulation in the Trump Administration.

By accident or design, FDA has chosen a particularly resonant case study for its first opioid formulation review of 2017,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership